EMA Authorised: Zoledronic acid Teva (zoledronic acid) — Teva B.V.

View source ↗

Summary

The EMA authorised Teva B.V.'s Zoledronic acid product for bone-related conditions and cancer-related bone disease. The active substance is zoledronic acid and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Hypercalcemia of Malignancy
• Multiple Myeloma
• Osteoporosis

Drugs mentioned

• Zoledronic acid (Teva) (zoledronic acid)

Snippet

Status: Authorised. Therapeutic area: Fractures, Bone;Cancer. MAH: Teva B.V.. Decision date: 24/09/2025